Tenofovir alafenamide fumarate

IF 1.3 4区医学 Q4 INFECTIOUS DISEASES

Antiviral Therapy Pub Date : 2022-02-01 DOI:10.1177/13596535211067600

William A Lee, A. Cheng

引用次数: 4

Abstract

Tenofovir alafenamide fumarate is a lipophilic prodrug of tenofovir which is preferentially metabolized in lymphatic tissue resulting in high concentrations of tenofovir (TFV) and its active diphosphate metabolite inside the cells that replicate HIV. Due to its selectivity for these tissues, lower total doses of TAF can be administered relative to tenofovir disoproxil fumarate (TDF) which results in improved bone and renal biomarkers. Tenofovir alafenamide fumarate has become the “backbone” of multiple combination products for the treatment of HIV, combined with emtricitabine for PreP and as a monotherapy for the treatment or HBV.

查看原文本刊更多论文

富马酸替诺福韦

富马酸替诺福韦阿拉胺是替诺福韦的亲脂性前药，在淋巴组织中优先代谢，导致在复制HIV的细胞内产生高浓度的替诺福韦(TFV)及其活性二磷酸代谢物。由于其对这些组织的选择性，相对于富马酸替诺福韦二氧吡酯(TDF)， TAF的总剂量可以降低，从而改善骨骼和肾脏生物标志物。富马酸替诺福韦阿拉那胺已成为治疗HIV的多种联合产品的“骨干”，与恩曲他滨联合用于PreP，并作为治疗HBV的单一疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antiviral Therapy 医学-病毒学

CiteScore

2.60

自引率

8.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Antiviral Therapy (an official publication of the International Society of Antiviral Research) is an international, peer-reviewed journal devoted to publishing articles on the clinical development and use of antiviral agents and vaccines, and the treatment of all viral diseases. Antiviral Therapy is one of the leading journals in virology and infectious diseases. The journal is comprehensive, and publishes articles concerning all clinical aspects of antiviral therapy. It features editorials, original research papers, specially commissioned review articles, letters and book reviews. The journal is aimed at physicians and specialists interested in clinical and basic research.